SoftWave® Tissue Regeneration Technologies, a disruptive bio-medical device company, announces the beginning of a trial for “Extracorporeal Shock Wave Therapy in Acute Traumatic Complete and Incomplete Cross – Sectional Lesions.” The trial will be sponsored by the Austrian Workers’ Compensation Board (AUVA). It will be conducted in 13 hospitals in Austria and one in Germany,...Read More
ATLANTA, May 19, 2021 (Newswire) – SoftWave Tissue Regeneration Technologies patented extracorporeal shock wave device called the OrthGold 100® was cleared by the FDA on May 4, 2021, for the indications of a temporary increase in local blood circulation, relief of minor aches and pains, and activation of connective tissue. (FDA 510(k) letter-number K210451.) According to...Read More
Kenneth Craig Vincent, Wolfgang Schaden, Laupepa Aposetolo Karalus, Jacqueline Craig Huges, Daniel Poratt – The ‘Niche’ is not merely an anatomical grid, but rather a dynamic communications conduit, sensing & transmitting signals (ie. biomechanical, chemical etc.) relaying the status & requirements of the tissue to its ‘Regenerative Cell’ source the Satellite Cells. Negative alterations or disruptions to...Read More
he physical shaking of the tissue by the shock waves leads to a mechanotransduction; the conversion of mechanical signals (e. g. shear, compression, tension) into electrical or chemical signals responses in the tissue. Click here to read more.Read More
Director Kompass Health Associates, Centre for Regenerative Health, Sports Performance & Research – Auckland, New Zealand; Director Shockwave & Isokinetic Centre – Melbourne, Australia; Sr. Surgeon & Adj. Prof. AUVA-Trauma Centre & Ludwig Boltzmann Institute of Experimental & Clinical Traumatology – Vienna, Austria; Director Kinematics Centre – Victoria, Australia; Research Assistant BHSc.(Health Sciences) PG Dip....Read More
